Tenofovir Alafenamide

Antiviral, Systemic · Nucleoside reverse transcriptase inhibitor

Indications

Treatment of chronic hepatitis B infection in adults with compensated liver disease.

Dosage

Adults: 25 mg once daily.

Adverse Effects

Nausea, headache, fatigue, abdominal pain, back pain, decreased bone mineral density, cough, increased LDL cholesterol, increased amylase, glycosuria, increased serum ALT and AST, increased serum creatine phosphokinase.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Controlled studies shown no risk. Lactation: Contraindicated or not recommended. Contraindications: Patients with Child-Pugh class B or C hepatic impairment. Patients with CrCl<15 mL/min. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. Precautions: Assess serum creatinine, estimated creatinine clearance, serum phosphorus, urine protein and urine glucose prior to initiation of treatment and during treatment.

Interactions

Avoid; Adefovir, carbamazepine, Fosphenytoin-Phenytoin, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, St John’s wort, tipranavir.

Advice to Patient

Take with meals.

Pharmacokinetics

Metabolism: Tenofovir alafenamide (TAF) is converted intracellulary to tenofovir, then phosphorylated to the active tenofovir diphosphate. Bioavailability: Increases approx. 65% with a high-fat meal. Half-life elimination: 0.51 hrs. Time to peak, serum: 0.48 hrs. Excretion: Faeces (31.7%). Urine (<1%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.